Literature DB >> 6734032

Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: difference in levodopa tolerance.

L Rivera-Calimlim, D K Reilly.   

Abstract

The same bimodal distribution of erythrocyte catechol-O-methyltransferase (RBC-COMT) was found in normal Caucasians and Orientals, but the frequency distribution of high RBC-COMT activity of the Orientals was significantly greater than that of the Caucasians. There was no difference in RBC-COMT frequency distribution between Oriental ethnic groups studied (i.e., Chinese and Filipinos). Since Caucasians with Parkinson's disease who had high RBC-COMT activity appeared to have more adverse effects from levodopa (L-dopa) than had those with low RBC-COMT activity, L-dopa doses and adverse responses in Filipinos with parkinsonism were compared to those of Caucasians with parkinsonism. The Filipinos were prescribed substantially lower doses than were the Caucasian patients, and more Filipinos than Caucasians developed dyskinesia at comparable doses of L-dopa. The possible association of the clinical differences in L-dopa tolerance and response between Filipinos and Caucasians with Parkinson's disease, with the racial differences in RBC-COMT activity is discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6734032     DOI: 10.1038/clpt.1984.116

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  14 in total

Review 1.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

2.  Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.

Authors:  Oscar Solís; Jose-Rubén García-Montes; Patricia Garcia-Sanz; Antonio S Herranz; Maria-José Asensio; Gina Kang; Noboru Hiroi; Rosario Moratalla
Journal:  Neurobiol Dis       Date:  2017-03-16       Impact factor: 5.996

3.  IPX066: a new intermediate-and extended-release carbidopa-levodopa formulation.

Authors:  Talene A Yacoubian
Journal:  Neurodegener Dis Manag       Date:  2013-04-01

4.  Catechol-O-methyltransferase genotype and susceptibility to Parkinson's disease in Japan. Short communication.

Authors:  A Yoritaka; N Hattori; H Yoshino; Y Mizuno
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

5.  Association of Ala72Ser polymorphism with COMT enzyme activity and the risk of schizophrenia in Koreans.

Authors:  Seong-Gene Lee; Yeonho Joo; Byungsu Kim; Seockhoon Chung; Hie-Lim Kim; Inchul Lee; Boyoul Choi; Changyoon Kim; Kyuyoung Song
Journal:  Hum Genet       Date:  2005-01-12       Impact factor: 4.132

6.  Catechol-O-methyltransferase (COMT) gene variants: possible association of the Val158Met variant with opiate addiction in Hispanic women.

Authors:  Bronson E Oosterhuis; K Steven LaForge; Dmitri Proudnikov; Ann Ho; David A Nielsen; Robert Gianotti; Sandra Barral; Derek Gordon; Suzanne M Leal; Jurg Ott; Mary Jeanne Kreek
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-09-05       Impact factor: 3.568

7.  Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients.

Authors:  Ying-Zi Liu; Bei-Sha Tang; Xin-Xiang Yan; Jie Liu; Dong-Sheng Ouyang; Li-Nuo Nie; Lan Fan; Zhi Li; Wei Ji; Dong-Li Hu; Dan Wang; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2009-04-25       Impact factor: 2.953

8.  Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians.

Authors:  M Jurima; T Inaba; D Kadar; W Kalow
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

9.  Low catechol-O-methyltransferase activity in a Saami population.

Authors:  B Klemetsdal; B Straume; T Giverhaug; J Aarbakke
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

10.  Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.

Authors:  Ahmed A Othman; Krai Chatamra; Mohamed-Eslam F Mohamed; Sandeep Dutta; Janet Benesh; Masayoshi Yanagawa; Masahiro Nagai
Journal:  Clin Pharmacokinet       Date:  2015-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.